Advances in molecular biomarkers research and clinical application progress for gastric cancer immunotherapy

Gastric cancer is characterized by high morbidity and mortality worldwide. Early-stage gastric cancer is mainly treated with surgery, while for advanced gastric cancer, the current treatment options remain insufficient. In the 2022 NCCN Guidelines for Gastric Cancer, immunotherapy is listed as a fir...

Descripción completa

Detalles Bibliográficos
Autores principales: Cai, Hongzhen, Li, Man, Deng, Ruiyi, Wang, Mopei, Shi, Yanyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9426247/
https://www.ncbi.nlm.nih.gov/pubmed/36042469
http://dx.doi.org/10.1186/s40364-022-00413-0
_version_ 1784778642837995520
author Cai, Hongzhen
Li, Man
Deng, Ruiyi
Wang, Mopei
Shi, Yanyan
author_facet Cai, Hongzhen
Li, Man
Deng, Ruiyi
Wang, Mopei
Shi, Yanyan
author_sort Cai, Hongzhen
collection PubMed
description Gastric cancer is characterized by high morbidity and mortality worldwide. Early-stage gastric cancer is mainly treated with surgery, while for advanced gastric cancer, the current treatment options remain insufficient. In the 2022 NCCN Guidelines for Gastric Cancer, immunotherapy is listed as a first-line option for certain conditions. Immunotherapy for gastric cancer mainly targets the PD-1 molecule and achieves therapeutic effects by activating T cells. In addition, therapeutic strategies targeting other molecules, such as CTLA4, LAG3, Tim3, TIGIT, and OX40, have also been developed to improve the treatment efficacy of gastric cancer immunotherapy. This review summarizes the molecular biomarkers of gastric cancer immunotherapy and their clinical trials.
format Online
Article
Text
id pubmed-9426247
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-94262472022-08-31 Advances in molecular biomarkers research and clinical application progress for gastric cancer immunotherapy Cai, Hongzhen Li, Man Deng, Ruiyi Wang, Mopei Shi, Yanyan Biomark Res Review Gastric cancer is characterized by high morbidity and mortality worldwide. Early-stage gastric cancer is mainly treated with surgery, while for advanced gastric cancer, the current treatment options remain insufficient. In the 2022 NCCN Guidelines for Gastric Cancer, immunotherapy is listed as a first-line option for certain conditions. Immunotherapy for gastric cancer mainly targets the PD-1 molecule and achieves therapeutic effects by activating T cells. In addition, therapeutic strategies targeting other molecules, such as CTLA4, LAG3, Tim3, TIGIT, and OX40, have also been developed to improve the treatment efficacy of gastric cancer immunotherapy. This review summarizes the molecular biomarkers of gastric cancer immunotherapy and their clinical trials. BioMed Central 2022-08-30 /pmc/articles/PMC9426247/ /pubmed/36042469 http://dx.doi.org/10.1186/s40364-022-00413-0 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Cai, Hongzhen
Li, Man
Deng, Ruiyi
Wang, Mopei
Shi, Yanyan
Advances in molecular biomarkers research and clinical application progress for gastric cancer immunotherapy
title Advances in molecular biomarkers research and clinical application progress for gastric cancer immunotherapy
title_full Advances in molecular biomarkers research and clinical application progress for gastric cancer immunotherapy
title_fullStr Advances in molecular biomarkers research and clinical application progress for gastric cancer immunotherapy
title_full_unstemmed Advances in molecular biomarkers research and clinical application progress for gastric cancer immunotherapy
title_short Advances in molecular biomarkers research and clinical application progress for gastric cancer immunotherapy
title_sort advances in molecular biomarkers research and clinical application progress for gastric cancer immunotherapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9426247/
https://www.ncbi.nlm.nih.gov/pubmed/36042469
http://dx.doi.org/10.1186/s40364-022-00413-0
work_keys_str_mv AT caihongzhen advancesinmolecularbiomarkersresearchandclinicalapplicationprogressforgastriccancerimmunotherapy
AT liman advancesinmolecularbiomarkersresearchandclinicalapplicationprogressforgastriccancerimmunotherapy
AT dengruiyi advancesinmolecularbiomarkersresearchandclinicalapplicationprogressforgastriccancerimmunotherapy
AT wangmopei advancesinmolecularbiomarkersresearchandclinicalapplicationprogressforgastriccancerimmunotherapy
AT shiyanyan advancesinmolecularbiomarkersresearchandclinicalapplicationprogressforgastriccancerimmunotherapy

Ejemplares similares